Equities research analysts expect LivaNova PLC (NASDAQ:LIVN) to report $0.97 earnings per share for the current fiscal quarter, Zacks Investment Research reports. Three analysts have provided estimates for LivaNova’s earnings. The highest EPS estimate is $0.97 and the lowest is $0.96. LivaNova posted earnings of $1.12 per share during the same quarter last year, which would indicate a negative year over year growth rate of 13.4%. The firm is scheduled to issue its next earnings results on Wednesday, February 26th.
On average, analysts expect that LivaNova will report full year earnings of $3.05 per share for the current year. For the next financial year, analysts anticipate that the business will report earnings of $3.31 per share, with EPS estimates ranging from $3.30 to $3.33. Zacks Investment Research’s EPS averages are a mean average based on a survey of research analysts that that provide coverage for LivaNova.
LivaNova (NASDAQ:LIVN) last released its quarterly earnings data on Wednesday, October 30th. The company reported $0.84 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.75 by $0.09. LivaNova had a negative net margin of 20.35% and a positive return on equity of 9.44%. The company had revenue of $268.60 million during the quarter, compared to analyst estimates of $273.41 million. During the same quarter in the prior year, the business earned $0.78 earnings per share. The business’s quarterly revenue was down 1.3% compared to the same quarter last year.
A number of brokerages recently weighed in on LIVN. ValuEngine raised shares of LivaNova from a “hold” rating to a “buy” rating in a research report on Thursday, November 7th. Piper Jaffray Companies set a $90.00 price objective on LivaNova and gave the stock a “buy” rating in a research note on Friday, September 6th. Needham & Company LLC reaffirmed a “buy” rating and issued a $88.00 target price on shares of LivaNova in a research report on Wednesday, November 20th. Zacks Investment Research lowered LivaNova from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, October 2nd. Finally, BidaskClub lowered LivaNova from a “strong-buy” rating to a “buy” rating in a research note on Thursday, December 5th. Three analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. The company presently has an average rating of “Buy” and a consensus target price of $96.00.
In other news, CEO Damien Mcdonald sold 1,000 shares of the firm’s stock in a transaction dated Monday, December 2nd. The stock was sold at an average price of $83.71, for a total transaction of $83,710.00. Following the completion of the sale, the chief executive officer now directly owns 66,016 shares in the company, valued at $5,526,199.36. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Daniel Jeffrey Moore sold 1,500 shares of LivaNova stock in a transaction dated Monday, September 16th. The stock was sold at an average price of $84.56, for a total value of $126,840.00. Over the last three months, insiders have sold 7,500 shares of company stock worth $598,070. Corporate insiders own 0.41% of the company’s stock.
Several large investors have recently added to or reduced their stakes in the stock. Price T Rowe Associates Inc. MD boosted its holdings in LivaNova by 18.8% in the second quarter. Price T Rowe Associates Inc. MD now owns 2,395,068 shares of the company’s stock valued at $172,349,000 after purchasing an additional 378,564 shares during the last quarter. Invesco Ltd. grew its stake in LivaNova by 376.8% during the 2nd quarter. Invesco Ltd. now owns 2,299,007 shares of the company’s stock valued at $165,437,000 after purchasing an additional 1,816,788 shares in the last quarter. UBS Asset Management Americas Inc. grew its stake in LivaNova by 22.9% during the 2nd quarter. UBS Asset Management Americas Inc. now owns 1,390,299 shares of the company’s stock valued at $100,046,000 after purchasing an additional 259,369 shares in the last quarter. Wells Fargo & Company MN increased its holdings in LivaNova by 11.5% during the 2nd quarter. Wells Fargo & Company MN now owns 1,322,072 shares of the company’s stock worth $95,136,000 after purchasing an additional 136,777 shares during the last quarter. Finally, Northern Trust Corp increased its holdings in LivaNova by 0.6% during the 2nd quarter. Northern Trust Corp now owns 778,763 shares of the company’s stock worth $56,040,000 after purchasing an additional 4,317 shares during the last quarter. Institutional investors and hedge funds own 87.80% of the company’s stock.
NASDAQ:LIVN opened at $80.47 on Tuesday. The company has a current ratio of 1.17, a quick ratio of 0.81 and a debt-to-equity ratio of 0.21. The firm has a market capitalization of $4.03 billion, a price-to-earnings ratio of 29.03, a PEG ratio of 3.80 and a beta of 0.59. The firm’s fifty day simple moving average is $77.67 and its 200 day simple moving average is $75.76. LivaNova has a twelve month low of $64.80 and a twelve month high of $102.43.
LivaNova Company Profile
LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. It operates in two segments, Cardiovascular (CV) and Neuromodulation (NM). The CV segment develops, produces, and sells cardiopulmonary products, including heart-lung machines, oxygenators, perfusion tubing sets, cannulae, and accessories, as well as related equipment and disposables for autotransfusion and autologous blood washing for neonatal, pediatric, and adult patients.
Further Reading: What is a Candlestick Chart?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for LivaNova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LivaNova and related companies with MarketBeat.com's FREE daily email newsletter.